An Acquisition & a Collaboration You Must Know About

Bristol-Myers Squibb
Increased activity being observed at Bristol-Myers Squibb (BMY) is aimed at further empowering the firm's various franchises. It all started with the firm’s attempt to empower its oncology franchise with the creation and approval of its checkpoint protein inhibitor Opdivo (nivolumab) - a programmed Death-1 (PD-1) inhibitor. This antibody has been the most successful attempt . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.